Glaukos Corporation $GKOS Shares Acquired by Westfield Capital Management Co. LP

Westfield Capital Management Co. LP boosted its holdings in shares of Glaukos Corporation (NYSE:GKOS) by 5.5% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,231,641 shares of the medical instruments supplier’s stock after purchasing an additional 63,788 shares during the period. Westfield Capital Management Co. LP owned about 2.14% of Glaukos worth $100,440,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also modified their holdings of the stock. UMB Bank n.a. boosted its stake in shares of Glaukos by 102.6% in the third quarter. UMB Bank n.a. now owns 312 shares of the medical instruments supplier’s stock worth $25,000 after buying an additional 158 shares during the last quarter. REAP Financial Group LLC purchased a new stake in Glaukos in the 3rd quarter worth approximately $40,000. AlphaQuest LLC increased its holdings in shares of Glaukos by 5,754.5% during the 2nd quarter. AlphaQuest LLC now owns 644 shares of the medical instruments supplier’s stock valued at $67,000 after purchasing an additional 633 shares in the last quarter. Smartleaf Asset Management LLC lifted its stake in shares of Glaukos by 16.2% in the 2nd quarter. Smartleaf Asset Management LLC now owns 973 shares of the medical instruments supplier’s stock valued at $99,000 after purchasing an additional 136 shares during the period. Finally, SBI Securities Co. Ltd. boosted its holdings in Glaukos by 42.9% during the third quarter. SBI Securities Co. Ltd. now owns 1,205 shares of the medical instruments supplier’s stock worth $98,000 after buying an additional 362 shares in the last quarter. Hedge funds and other institutional investors own 99.04% of the company’s stock.

Glaukos Stock Up 1.7%

Shares of GKOS opened at $121.25 on Thursday. The stock has a 50 day moving average price of $115.75 and a 200 day moving average price of $99.63. Glaukos Corporation has a one year low of $73.16 and a one year high of $130.23. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.06 and a current ratio of 4.69. The stock has a market capitalization of $7.04 billion, a price-to-earnings ratio of -37.19 and a beta of 0.70.

Glaukos (NYSE:GKOS) last announced its earnings results on Tuesday, February 17th. The medical instruments supplier reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.06). Glaukos had a negative return on equity of 7.00% and a negative net margin of 36.99%.The business had revenue of $143.12 million for the quarter, compared to analyst estimates of $132.16 million. During the same period last year, the firm earned ($0.40) EPS. The company’s revenue for the quarter was up 35.6% compared to the same quarter last year. Equities research analysts forecast that Glaukos Corporation will post -1.08 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

GKOS has been the subject of a number of analyst reports. Wells Fargo & Company upped their price objective on shares of Glaukos from $122.00 to $135.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 18th. UBS Group raised their price objective on Glaukos from $140.00 to $145.00 and gave the company a “buy” rating in a report on Tuesday, December 23rd. Stephens upped their target price on Glaukos from $115.00 to $145.00 and gave the stock an “overweight” rating in a research note on Friday, January 2nd. JPMorgan Chase & Co. lifted their price target on shares of Glaukos from $110.00 to $120.00 and gave the company an “overweight” rating in a research note on Thursday, October 30th. Finally, The Goldman Sachs Group reissued a “buy” rating and issued a $138.00 price target on shares of Glaukos in a report on Friday, January 9th. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $133.69.

Insider Activity

In other Glaukos news, Director Gilbert H. Kliman sold 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $107.27, for a total value of $536,350.00. Following the transaction, the director directly owned 34,905 shares of the company’s stock, valued at $3,744,259.35. This trade represents a 12.53% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Thomas William Burns sold 186,945 shares of the company’s stock in a transaction that occurred on Friday, January 16th. The shares were sold at an average price of $115.00, for a total value of $21,498,675.00. Following the completion of the sale, the chief executive officer owned 153,775 shares of the company’s stock, valued at $17,684,125. This trade represents a 54.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 325,000 shares of company stock valued at $37,739,259 in the last ninety days. 5.80% of the stock is currently owned by corporate insiders.

Glaukos Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.